ReviewCardiac failure review2019
Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice.
Review in Cardiac failure review, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Factors Associated with Progression to SCAI-Defined Hemodynamic Instability at 72 Hours in Patients with Acute Decompensated Heart Failure Receiving Inotropic Therapy.Journal of clinical medicine · 2026Article
- Istaroxime in Acute Heart Failure and Early Cardiogenic Shock: A Calcium-Cycling Approach to Inotropic Therapy.International journal of molecular sciences · 2026Review
- Present and Future Options for Pharmacotherapy in Cardiovascular Disease: Hemodynamic and Mechanistic Therapeutic Targets.Medical sciences (Basel, Switzerland) · 2026Review
- Review
- Dopamine-Induced Seizure in a Heart Failure Patient: A Case Report and Review of Neurotoxic Implications.Clinical case reports · 2026Article
- Levosimendan in Cardiogenic Shock: A Review of Mechanisms, Clinical Evidence, and Therapeutic Use.Reviews in cardiovascular medicine · 2026Review
- Utilization patterns and determinants of guideline-recommended therapies for acute heart failure in Denmark.European heart journal. Acute cardiovascular care · 2026Article
- Tailoring heart failure management in cardiac amyloidosis.Heart failure reviews · 2026Review
- Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.Annals of medicine and surgery (2012) · 2025Review
- The heart, a secondary organ in the control of blood circulation.Experimental physiology · 2025Review
- Cardiac Indices Parameters on the Ultrasonic Cardiac Output Monitor as Potential Indicators to Predict the Ultrafiltration Endpoint Success in Acute Heart Failure Treatment.Reviews in cardiovascular medicine · 2025Article
- Ventricular Arrhythmias in Severe Aortic Stenosis Prior to Aortic Valve Replacement: A Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Review
- Article
- Transition to Advanced Heart Failure: From Identification to Improving Prognosis.Journal of cardiovascular development and disease · 2025Review
- Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF).Current vascular pharmacology · 2025Observational
- Managing Arrhythmias in Cardiogenic Shock: Insights Into Milrinone and Dobutamine Therapy.Cureus · 2024Review
- Neurohormonal Effects of Intravenous Dopamine in Patients with Acute Heart Failure.Journal of clinical medicine · 2024Article
- Navigating Pediatric Cor Pulmonale: A Comprehensive Review of Diagnosis and Management.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inotropes are pharmacological agents that are indicated for the treatment of patients presenting with acute heart failure (AHF) with concomitant hypoperfusion due to decreased cardiac output. They are usually administered for a short period during the initial management of AHF until haemodynamic stabilisation and restoration of peripheral perfusion occur. They can be used for longer periods to support patients as a bridge to a more definite treatment, such as transplant of left ventricular assist devices, or as part of a palliative care regimen. The currently available inotropic agents in clinical practice fall into three main categories: beta-agonists, phosphodiesterase III inhibitors and calcium sensitisers. However, due to the well-documented potential for adverse events and their association with increased long-term mortality, physicians should be aware of the indications and dosing strategies suitable for different types of patients. Novel inotropes that use alternative intracellular pathways are under investigation, in an effort to minimise the drawbacks that conventional inotropes exhibit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.